Latigo Biotherapeutics, Inc. (LTGO) earnings
Quarterly results of Latigo Biotherapeutics, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 6 quarters, the latest results release and when the next one is expected.
Latest quarter: Q3 FY2026
In Q3 FY2026 (ended September 30, 2026) Latigo Biotherapeutics, Inc. reported revenue of - and a net loss of $20.9M.
Diluted earnings per share were -$0.55.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q3 FY2026 | - | - | -$20.9M | -$0.55 |
| Q2 FY2026 | - | - | -$25.8M | -$27.59 |
| Q2 FY2026 | - | - | -$23M | - |
| Q3 FY2026 | - | - | -$24.8M | -$29.50 |
| Q2 FY2026 | - | - | -$25.8M | -$36.52 |
| Q2 FY2026 | - | - | -$21M | - |
Results filings
- Quarterly report 10-Q
- Quarterly results 8-K
- Quarterly report 10-Q
- Quarterly results 8-K
Get an email when LTGO reports
Follow LTGO and we email you its next results the day they are filed, with the numbers explained.